COMMUNIQUÉS West-GlobeNewswire
-
Channel Medsystems Strengthens Commercial Leadership Team with Appointments of Tara Murphy as Vice President of Marketing and Paul Russo as Vice President of Sales
16/10/2025 -
HCW Biologics to Participate in the 2025 Maxim Growth Summit
16/10/2025 -
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
16/10/2025 -
Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit
16/10/2025 -
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
16/10/2025 -
CJ Biomaterials Introduces New PHACT™ PHA Masterbatch for Safer, Stronger, Softer, Home Compostable Spunbond Nonwovens and Staple Fiber
16/10/2025 -
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
16/10/2025 -
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
16/10/2025 -
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
16/10/2025 -
Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
16/10/2025 -
Catheter Precision Enters Distribution Agreement with FuMedica AG to Bring LockeT to Switzerland
16/10/2025 -
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
16/10/2025 -
PetVivo Animal Health, Inc. Enters Vendor Partner Agreement with Veterinary Growth Partners to Expand Access to Innovative Veterinary Therapeutics
16/10/2025 -
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
16/10/2025 -
Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
16/10/2025 -
Belite Bio to Participate in the 2025 Maxim Growth Summit
16/10/2025 -
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
16/10/2025 -
Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
16/10/2025 -
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
16/10/2025
Pages